skip navigation

Skip Nav

Clinical Guidelines Portal

Clinical Guidelines Portal

Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents

Mucocutaneous Candidiasis

(Last updated:May 07, 2013; last reviewed:May 07, 2013)

Epidemiology

Oropharyngeal and esophageal candidiasis are common in HIV-infected patients.1,2 Most such infections are caused by Candida albicans. The occurrence of oropharyngeal or esophageal candidiasis is recognized as an indicator of immune suppression and is most often observed in patients with CD4 T lymphocyte (CD4) cell counts <200 cells/mm3, with esophageal disease typically occurring at lower CD4 counts than oropharyngeal disease.1,2 In contrast, vulvovaginal candidiasis—whether single episode or recurrent—is common in healthy, adult women and does not suggest HIV infection. The advent of highly active antiretroviral therapy (HAART) has led to a dramatic decline in the prevalence of oropharyngeal and esophageal candidiasis and a marked diminution in cases of refractory disease.

Fluconazole (or azole) resistance is predominantly the consequence of previous exposure to fluconazole (or other azoles), particularly repeated and long-term exposure.3-5 In this setting, C. albicans resistance has been associated with a gradual emergence of non-albicans Candida species, particularly Candida glabrata, as a cause of refractory mucosal candidiasis in patients with advanced immunosuppression and low CD4 counts.3,6

Clinical Manifestations

Oropharyngeal candidiasis is characterized by painless, creamy white, plaque-like lesions that can occur on the buccal surface, hard or soft palate, oropharyngeal mucosa, or tongue surface. Lesions can be easily scraped off with a tongue depressor or other instrument. Less commonly, erythematous patches without white plaques can be seen on the anterior or posterior upper palate or diffusely on the tongue. Angular cheilosis also can be caused by Candida.

Esophageal candidiasis generally presents with retrosternal burning pain or discomfort along with odynophagia; occasionally esophageal candidiasis can be asymptomatic. Endoscopic examination reveals whitish plaques similar to those observed with oropharyngeal disease. On occasion, the plaques may progress to superficial ulcerations of the esophageal mucosa with central or peripheral whitish exudates.

In HIV-infected women with early-stage disease, Candida vulvovaginitis usually presents as it does in HIV-uninfected women, with white adherent vaginal discharge associated with mucosal burning and itching of mild-to-moderate severity and sporadic recurrences. In women with advanced immunosuppression, episodes may be more severe and recur more frequently. In contrast to oropharyngeal candidiasis, vulvovaginal candidiasis is less common and rarely refractory to azole therapy.

Diagnosis

Oropharyngeal candidiasis is usually diagnosed clinically based on the characteristic appearance of lesions. In contrast to oral hairy leukoplakia, the white plaques of oropharyngeal candidiasis can be scraped off the mucosa. If laboratory confirmation is required, scrapings can be examined microscopically for characteristic yeast or hyphal forms, using a potassium hydroxide preparation. Cultures of clinical exudative material yield the species of Candida present.

The definitive diagnosis of esophageal candidiasis requires direct endoscopic visualization of lesions with histopathologic demonstration of characteristic Candida yeast forms in tissue and confirmation by fungal culture and speciation. The diagnosis is often made empirically based on symptoms plus response to therapy, or visualization of lesions plus fungal smear or brushings without histopathologic examination. 

Vulvovaginal candidiasis usually is diagnosed based on the clinical presentation coupled with the demonstration of characteristic blastosphere and hyphal yeast forms in vaginal secretions when examined microscopically after potassium hydroxide preparation. Culture confirmation is rarely required but may provide supportive information. Self-diagnosis of vulvovaginitis is unreliable; microscopic and culture confirmation is required to avoid unnecessary exposure to treatment.

Preventing Exposure

Candida organisms are common commensals on mucosal surfaces in healthy individuals. No measures are available to reduce exposure to these fungi.

Preventing Disease

Data from prospective controlled trials indicate that fluconazole can reduce the risk of mucosal disease (i.e., oropharyngeal, esophageal, and vulvovaginal) in patients with advanced HIV.7-10 However, routine primary prophyalxis is not recommended because mucosal disease is associated with very low attributable morbidity and mortality and, moreover, acute therapy is highly effective. Primary antifungal prophylaxis can lead to infections caused by drug-resistant Candida species and introduce significant drug-drug interactions. In addition long-term oral prophylaxis is expensive. Therefore, routine primary prophylaxis is not recommended (AIII).

Treating Disease

Oral fluconazole is as effective as and, in certain studies, superior to topical therapy for oropharyngeal candidiasis. In addition, oral therapy is more convenient than topical therapy and usually better tolerated. Therefore, oral fluconazole is considered the drug of choice to treat oropharyngeal candidiasis (AI).11 Using topical rather than systemic oral therapy reduces systemic drug exposure, diminishes risk of drug-drug interactions and systemic adverse events, and possibly decreases the development of secondary antifungal resistance. Mild-to-moderate episodes of oropharyngeal candidiasis can be adequately treated with topical therapy, including once-daily miconazole in 50-mg mucoadhesive buccal tablets (BI) or clotrimazole troches 5 times daily (BI). In a multi-center, randomized study among HIV-infected individuals, 50-mg mucoadhesive buccal tablets of miconazole applied once daily to the mucosal surface over the canine fossa were as effective as 10-mg clotrimazole troches used 5 times daily.12 Nystatin suspension or pastilles four times daily remain an additional alternative (BII).13

Itraconazole oral solution for 7 to 14 days is as effective as oral fluconazole for oropharyngeal candidiasis but less well tolerated (BI).13 Posaconazole oral solution14 also is as effective as fluconazole and generally better tolerated than itraconazole solution (BI). Both antifungals are alternatives to oral fluconazole, although few situations require that these drugs be used in preference to fluconazole solely to treat mucosal candidiasis. In a multicenter, randomized study, posaconazole was proven more effective than fluconazole in sustaining clinical success after antifungal therapy was discontinued.14 Itraconazole capsules are less effective than fluconazole because of their more variable absorption and they are associated with more drug-drug interactions than fluconazole. 

Systemic antifungals are required for effective treatment of esophageal candidiasis (AI). A 14- to 21-day course of either fluconazole (oral or intravenous [IV]) or oral itraconazole solution is highly effective (AI). However, patients with severe symptoms initially may have difficulty swallowing oral drugs. As with oropharyngeal candidiasis, itraconazole capsules for esophageal candidiasis are less effective than fluconazole because of variable absorption (CII). Voriconazole, amphotericin B (either deoxycholate or lipid formulations) and the echinocandins caspofungin, micafungin, and anidulafungin all are effective in treating esophageal candidiasis (BI). However, esophageal candidiasis appears to have a higher relapse rate after treatment with the echinocandins.15,16 Therefore, oral or IV fluconazole remains the preferred therapy for esophageal candidiasis (AI). Although other pathogens (e.g., cytomegalovirus, herpes simplex virus esophagitis) can mimic the symptoms of esophageal candidiasis, a diagnostic and therapeutic trial of antifungal therapy is usually warranted before endoscopy. In those who do not respond to antifungal therapy, endoscopy is recommended to identify different causes of esophagitis or drug-resistant Candida (AII).

In most HIV-infected women, vulvovaginal candidiasis is uncomplicated and responds readily to short-course oral or topical treatment with any of several therapies, including:
  • Oral fluconazole (AII)
  • Topical azoles (clotrimazole, butoconazole, miconazole, tioconazole, or terconazole) (AII)
  • Itraconazole oral solution (BII)
Severe or recurrent episodes of vaginitis should be treated with oral fluconazole or topical antifungal therapy for ≥7 days (AII).

Special Considerations with Regard to Starting ART

There are no special considerations regarding initiation of antiretroviral therapy (ART) in patients with mucocutaneous candidiasis. Specifically, there is as yet no evidence that treatment with ART needs to be delayed until treatment for candidiasis has been completed.

Monitoring of Response to Therapy and Adverse Events (Including IRIS) 

For most patients with mucocutaneous candidiasis, response to antifungal therapy is rapid; signs and symptoms improve within 48 to 72 hours. Short courses of topical therapy rarely result in adverse effects, although patients may experience cutaneous hypersensitivity reactions characterized by rash and pruritus. Oral azole therapy can be associated with nausea, vomiting, diarrhea, abdominal pain, or transaminase elevations. Periodic monitoring of liver function studies should be considered if azole therapy is anticipated for >21 days, especially in patients with other hepatic comorbidities (AII). The echinocandins appear to be associated with very few adverse reactions: histamine-related infusion toxicity, transaminase elevations, and rash have been attributed to these drugs. No dose adjustments are required in renal failure.

Immune reconstitution inflammatory syndrome (IRIS) with ART has not yet been reported for mucocutaneous candidiasis in HIV-infected patients. Indeed, ART is associated with a markedly reduced incidence of candidiasis.

Managing Treatment Failure

Antifungal treatment failure is typically defined as the persistence of signs or symptoms of oropharyngeal or esophageal candidiasis after 7 to 14 days of appropriate antifungal therapy. Refractory disease occurs in approximately 4% to 5% of HIV-infected patients with oral or esophageal candidiasis, typically those with CD4 cell counts <50 cells/mm3 and who have received multiple courses of azole antifungals.4 Confirmatory culture and, in the case of esophageal candidiasis, endoscopy are necessary to confirm treatment failure due to azole resistance or other causes of esophagitis, especially if these procedures were not initially performed.

Posaconazole immediate-release oral suspension (400 mg twice daily for 28 days) is effective in 75% of patients with azole-refractory oropharyngeal or esophageal candidiasis (AI).17 Alternatively, oral itraconazole solution is effective, at least transiently, in approximately two-thirds of patients with fluconazole-refractory mucosal candidiasis (BII).13 If necessary, azole-refractory esophageal candidiasis also can be treated with anidulafungin (BII), caspofungin (BII), micafungin (BII), or voriconazole (BII).

IV amphotericin B is usually effective for treating refractory disease (BII). Both amphotericin B deoxycholate and the lipid preparations of amphotericin B have been used successfully (BII). Amphotericin B oral suspension (1 mL of the 100-mg/mL suspension 4 times daily) is sometimes effective in patients with oropharyngeal candidiasis who do not respond to itraconazole (BII), but this product is not commercially available in the United States.

Preventing Recurrence

When to Start Secondary Prophylaxis

A randomized clinical trial10 in HIV-infected patients with CD4 counts <150 cells/mm3 documented a significantly lower number of episodes of oropharyngeal candidiasis and other invasive fungal infections with continuous fluconazole therapy (3 times a week) compared with episodic fluconazole treatment for recurrences. This clinical trial also demonstrated no difference in the risk of developing clinically significant fluconazole resistance between the two groups among those receiving ART. 

However, secondary prophylaxis (chronic suppressive therapy) is not recommended by most HIV specialists for recurrent oropharyngeal or vulvovaginal candidiasis unless patients have frequent or severe recurrences (BIII) because therapy for acute disease is effective, mortality associated with mucocutaneous disease is low, potential exists for development of Candida-resistant organisms and drug interactions, and prophylaxis is costly. 

If recurrences are frequent or severe, oral fluconazole can be used as suppressive therapy for either oropharyngeal (BI), esophageal (BI), or vulvovaginal (BII) candidiasis.7-9 Oral posaconazole twice daily is also effective for esophageal candidiasis (BII).18 The potential for development of secondary azole resistance should be considered when contemplating chronic maintenance therapy using azoles in HIV-infected patients who are severely immunocompromised. Several important factors should be taken into account when making the decision to use secondary prophylaxis. These include the effect of recurrences on the patient’s well-being and quality of life, the need for prophylaxis against other fungal infections, cost, adverse events, and, most importantly, drug-drug interactions.19

Rates of relapse are high in patients with azole-refractory oropharyngeal or esophageal candidiasis who have initially responded to echinocandins, voriconazole, or posaconazole therapy. In such patients, secondary prophylaxis should be instituted until ART produces immune reconstitution (AIII).

When to Stop Secondary Prophylaxis

In situations where secondary prophylaxis has been instituted, no data exist to guide recommendations regarding its discontinuation. On the basis of experience with other opportunistic infections (OIs), it would be reasonable to discontinue secondary prophylaxis when the CD4 count has risen to >200 cells/mm3 following initiation of ART (AIII).

Special Considerations During Pregnancy

Pregnancy increases the risk of vaginal colonization with Candida species. Diagnosis of oropharyngeal, esophageal, and vulvovaginal candidiasis is the same in pregnant women as in those who are not pregnant.

Topical therapy is preferable for treatment of oral or vaginal candidiasis in pregnancy, when possible (AIII). Single-dose, episodic treatment with oral fluconazole has not been associated with birth defects in humans. However, five cases of a syndrome consisting of craniosynostosis, characteristic facies, digital synostosis, and limb contractures (fluconazole embryopathy) have been reported in women chronically prescribed fluconazole at doses of 400 mg daily or higher in pregnancy.20 On the basis of these data, substitution of amphotericin B for high-dose fluconazole in the first trimester is recommended for invasive or refractory esophageal candidal infections (AIII). Neonates born to women receiving chronic amphotericin B at delivery should be evaluated for renal dysfunction and hypokalemia. Itraconazole has been shown to be teratogenic in animals at high doses, but the metabolic mechanism accounting for these defects is not present in humans, so these data are not applicable. Case series in humans do not suggest an increased risk of birth defects with itraconazole,21 but experience is limited. Human data are not available for posaconazole; however, the drug was associated with skeletal abnormalities in rats and was embryotoxic in rabbits when given at doses that produced plasma levels equivalent to those seen in humans. Voriconazole is considered an FDA category D drug because of its association with cleft palate and renal defects seen in rats and embryotoxicity seen in rabbits. However, human data on the use of voriconazole are not available, so use in the first trimester is not recommended. Multiple anomalies have been seen in animals exposed to micafungin, and ossification defects have been seen with use of anidulafungin and caspofungin. Human data are not available for these drugs, thus their use in human pregnancy is not recommended (AIII).

Chemoprophylaxis, either chronic maintenance therapy or secondary prophylaxis, against oropharyngeal, esophageal, or vaginal candidiasis using systemically absorbed azoles should not be initiated during pregnancy (AIII). Furthermore, prophylaxis with systemic azoles should be discontinued in HIV-infected women who become pregnant (AIII).


Recommendations for Treating Mucosal Candidiasis

No title

Treating Mucosal Candidiasis

Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)

Preferred Oral Therapy:
  • Fluconazole 100 mg PO once daily (AI), or
Preferred Topical Therapy:
  • Clotrimazole troches 10 mg PO 5 times daily (BI), or
  • Miconazole mucoadhesive buccal tablet 50 mg: Apply to mucosal surface over the canine fossa once daily (do not swallow, chew, or crush tablet). Refer to product label for more detailed application instructions. (BI)
Alternative Oral Therapy:
  • Itraconazole oral solution 200 mg PO daily (BI), or
  • Posaconazole oral solution 400 mg PO BID once, then 400 mg daily (BI)
Alternative Topical Therapy:
  • Nystatin suspension 4–6 mL QID or 1–2 flavored pastilles 4–5 times daily (BII)
Esophageal candidiasis (Duration of Therapy: 14–21 days)

Note: Systemic antifungals are required for effective treatment of esophageal candidiasis (AI)

Preferred Therapy:
  • Fluconazole 100 mg (up to 400 mg) PO or IV daily (AI), or
  • Itraconazole oral solution 200 mg PO daily (AI)
Alternative Therapy:
  • Voriconazole 200 mg PO or IV BID (BI), or
  • Posaconazole 400 mg PO BID (BI), or
  • Caspofungin 50 mg IV daily (BI), or
  • Micafungin 150 mg IV daily (BI), or
  • Anidulafungin 100 mg IV x 1, then 50 mg IV daily (BI), or
  • Amphotericin B deoxycholate 0.6 mg/kg IV daily (BI), or
  • Lipid formulation of amphotericin B 3-4 mg/kg IV daily (BIII)
Note: Higher relapse rate of esophageal candidiasis with echinocandins than with fluconazole has been reported

Uncomplicated Vulvovaginal Candidiasis

Preferred Therapy:
  • Oral fluconazole 150 mg for 1 dose (AII)
  • Topical azoles (clotrimazole, butoconazole, miconazole, tioconazole, or terconazole) for 3–7 days (AII)
Alternative Therapy:
  • Itraconazole oral solution 200 mg PO daily for 3-7 days (BII)
Severe or recurrent vaginitis should be treated with oral fluconazole (100–200 mg) or topical antifungals for ≥7 days (AII)
Chronic Suppressive Therapy
  • Chronic suppressive therapy is usually not recommended unless patients have frequent or severe recurrences (BIII). 
  • If used, it is reasonable to discontinue therapy if CD4 >200 cells/µL (AIII). 
If Decision Is To Use Suppressive Therapy:

Oropharyngeal Candidiasis
  • Fluconazole 100 mg PO once daily or 3 times weekly (BI)
Esophageal Candidiasis
  • Fluconazole 100–200 mg PO daily (BI)
  • Posaconazole 400 mg PO BID (BII)
Vulvovaginal Candidiasis
  • Fluconazole 150 mg PO once weekly (BII)
Other Considerations:
  • Chronic or prolonged use of azoles might promote development of resistance.
  • Systemic azoles may have significant drug-drug interactions with ARV drugs and other drugs for treatment of OI; refer to Table 5 for dosing recommendations. Consider therapeutic drug monitoring if prolonged use is indicated.
Key to Acronyms: ARV = antiretroviral; BID = twice daily; CD4 = CD4 T lymphocyte cell; IV = intraveneously; OI = opportunistic infection; PO = orally; QID = four times daily

References

  1. Klein RS, Harris CA, Small CB, Moll B, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med. Aug 9 1984;311(6):354-358. Available at http://www.ncbi.nlm.nih.gov/pubmed/6738653.
  2. Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. Arch Intern Med. Aug 1991;151(8):1567-1572. Available at http://www.ncbi.nlm.nih.gov/pubmed/1651690.
  3. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother. Jan 1995;39(1):1-8. Available at http://www.ncbi.nlm.nih.gov/pubmed/7695288.
  4. Fichtenbaum CJ, Koletar S, Yiannoutsos C, et al. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clin Infect Dis. May 2000;30(5):749-756. Available at http://www.ncbi.nlm.nih.gov/pubmed/10816143.
  5. Maenza JR, Merz WG, Romagnoli MJ, Keruly JC, Moore RD, Gallant JE. Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology. Clin Infect Dis. Jan 1997;24(1):28-34. Available at http://www.ncbi.nlm.nih.gov/pubmed/8994752.
  6. Martins MD, Lozano-Chiu M, Rex JH. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin Infect Dis. Oct 1997;25(4):843-846. Available at http://www.ncbi.nlm.nih.gov/pubmed/9356799.
  7. Powderly WG, Finkelstein D, Feinberg J, et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med. Mar 16 1995;332(11):700-705. Available at http://www.ncbi.nlm.nih.gov/pubmed/7854376.
  8. Schuman P, Capps L, Peng G, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med. May 1 1997;126(9):689-696. Available at http://www.ncbi.nlm.nih.gov/pubmed/9139554.
  9. Havlir DV, Dube MP, McCutchan JA, et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis. Dec 1998;27(6):1369-1375. Available at http://www.ncbi.nlm.nih.gov/pubmed/9868644.
  10. Goldman M, Cloud GA, Wade KD, et al. A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis. Nov 15 2005;41(10):1473-1480. Available at http://www.ncbi.nlm.nih.gov/pubmed/16231260.
  11. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. Jan 15 2004;38(2):161-189. Available at http://www.ncbi.nlm.nih.gov/pubmed/14699449.
  12. Vazquez JA, Patton LL, Epstein JB, et al. Randomized, comparative, double-blind, double-dummy, multicenter trial of miconazole buccal tablet and clotrimazole troches for the treatment of oropharyngeal candidiasis: study of miconazole Lauriad(R) efficacy and safety (SMiLES). HIV Clin Trials. Jul-Aug 2010;11(4):186-196. Available at http://www.ncbi.nlm.nih.gov/pubmed/20974574.
  13. Vazquez JA. Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection. HIV AIDS (Auckl). 2010;2(1):89-101. Available at http://www.ncbi.nlm.nih.gov/pubmed/22096388.
  14. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis. Apr 15 2006;42(8):1179-1186. Available at http://www.ncbi.nlm.nih.gov/pubmed/16575739.
  15. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. Sep 15 2004;39(6):842-849. Available at http://www.ncbi.nlm.nih.gov/pubmed/15472817.
  16. Krause DS, Simjee AE, van Rensburg C, et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. Sep 15 2004;39(6):770-775. Available at http://www.ncbi.nlm.nih.gov/pubmed/15472806.
  17. Skiest DJ, Vazquez JA, Anstead GM, et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. Feb 15 2007;44(4):607-614. Available at http://www.ncbi.nlm.nih.gov/pubmed/17243069.
  18. Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials. Mar-Apr 2007;8(2):86-97. Available at http://www.ncbi.nlm.nih.gov/pubmed/17507324.
  19. Marty F, Mylonakis E. Antifungal use in HIV infection. Expert opinion on pharmacotherapy. Feb 2002;3(2):91-102. Available at http://www.ncbi.nlm.nih.gov/pubmed/11829723.
  20. Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth defects research. Part A, Clinical and molecular teratology. Nov 2005;73(11):919-923. Available at http://www.ncbi.nlm.nih.gov/pubmed/16265639.
  21. De Santis M, Di Gianantonio E, Cesari E, Ambrosini G, Straface G, Clementi M. First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy. Drug Saf. 2009;32(3):239-244. Available at http://www.ncbi.nlm.nih.gov/pubmed/19338381.

Back to Top